One of the things I always tell investors is to look for biotech companies that have a focus spread across a number of different opportunities. One of the keys to success is a strong pipeline with a variety of products, and, preferably, at least a few successful products already on the market. If you can find an investment opportunity with a varied portfolio, you are more likely to see growth than if you focus on companies that are banking on just one or two drugs.
The exception to this rule is Questcor Pharmaceuticals (QCOR). Questcor is a biopharmaceutical company with products designed to help patients who have serious, difficult-to-treat medical conditions. Its focus is on neurology and nephrology, as well as research efforts for a variety of conditions having significant unmet medical need. Although the company has two drugs currently on the market, the majority of its focus is on Acthar. The drug is capable of treating multiple sclerosis, infantile spasms, and nephrotic syndrome.The company’s stated business strategy is to increase revenue and sales by marketing to physicians focused on difficult to treat medical conditions, to leverage Acthar through investing and clinical research, and to actively provide physician and patient assistance programs and financial support to research programs at academic institutions. The company is obviously forward-thinking, despite focusing mainly on Acthar.This is why it is one of the few investment opportunities I recommend that does not have a diverse portfolio.To continue reading, click here.To continue reading, click here.